Navigation Links
NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
Date:12/6/2012

WALTHAM, Mass., Dec. 6, 2012 /PRNewswire/ -- NKT Therapeutics, Inc., a privately held biotechnology company, announced preclinical study results supporting the potential of its lead therapeutic candidate, NKTT120, as an innovative approach to the treatment of sickle cell disease. Preclinical studies of NKTT120, a humanized monoclonal antibody, showed its ability to generate a safe, rapid, specific and complete depletion of invariant Natural Killer T cells (iNKT cells) 24 hours post dosing, thus  offering a means to reduce the chronic inflammation associated with sickle cell disease pathology. NKT Therapeutics plans to initiate a clinical trial of NKTT120 in patients with stable sickle cell disease in the first quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20121203/MM23274LOGO)

The study will be presented on December 9 at the American Society of Hematology meeting in Atlanta as a poster presentation entitled, "The Safety Evaluation of NKTT120, an iNKT Cell Depleting Antibody in the Cynomolgus Monkey." An abstract of the study has been published online at https://ash.confex.com/ash/2012/webprogram/Paper50259.html

NKTT120 is a humanized monoclonal antibody that results in a safe, rapid, specific and complete depletion of iNKT cells. The presented research showed that a specific and complete depletion of iNKT cells was observed at the earliest post dosing measurement at 24 hours, and was maintained throughout the 85 day study. Investigators observed no adverse events, infections, or cytokine release.  T cell-dependent antibody response to KLH antigen was not affected by NKTT120 treatment. 

Chronic inflammation is associated with the pathology of sickle cell disease, and studies by NKT Therapeutics and others have found an increased ratio of activated iNKT cells in the peripheral blood of patients with sickle cell disease. These findings suggest that iNKT cell reduction and/or depletion would be effective in reducing the damaging inflammation associated with sickle cell disease.

"Depletion of iNKT cells represents an exciting new approach to the treatment of sickle cell disease, and we are encouraged that this mechanism has the potential to meaningfully improve the lives of patients with this condition," stated Dr. Robert Schaub, Chief Scientific Officer at NKT Therapeutics. 

"The safety and pharmacodynamic profile of NKTT120 demonstrated in this study  are extremely encouraging, and we look forward to testing this investigational agent in patients with stable sickle cell disease," added Dr. Joshua Field, Medical Director of the Adult Sickle Cell Disease Clinic at the Medical College of Wisconsin, and Principal Investigator of the planned study.

About NKT Therapeutics, Inc.

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat sickle cell disease, autoimmune and inflammatory diseases, and cancer. For more information on the company, please visit http://www.nktrx.com.

 


'/>"/>
SOURCE NKT Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
2. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
3. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
4. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
5. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
6. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
7. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
8. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
9. Alzheimers Therapeutics Reviewed by NeuroPerspective
10. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
11. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):